HBW Advisory Services LLC Grows Stock Position in Amgen Inc. (NASDAQ:AMGN)

HBW Advisory Services LLC boosted its position in Amgen Inc. (NASDAQ:AMGN) by 1.0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 8,559 shares of the medical research company’s stock after buying an additional 88 shares during the period. HBW Advisory Services LLC’s holdings in Amgen were worth $2,231,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the company. Capital Performance Advisors LLP purchased a new stake in shares of Amgen during the 3rd quarter worth $25,000. Strategic Financial Concepts LLC acquired a new stake in shares of Amgen in the second quarter valued at about $26,000. Legacy Investment Solutions LLC purchased a new stake in Amgen during the third quarter worth about $29,000. Hershey Financial Advisers LLC acquired a new position in Amgen during the second quarter worth about $30,000. Finally, Matrix Trust Co purchased a new position in Amgen in the third quarter valued at about $36,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently commented on AMGN. Royal Bank of Canada decreased their price target on Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 27th. Citigroup lowered their target price on Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $405.00 price target on shares of Amgen in a research note on Tuesday, October 22nd. Piper Sandler lowered their price objective on shares of Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a research note on Thursday, January 2nd. Finally, William Blair restated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $314.91.

Amgen Trading Down 1.3 %

Shares of NASDAQ AMGN traded down $3.46 during midday trading on Friday, hitting $260.75. The stock had a trading volume of 1,422,272 shares, compared to its average volume of 2,820,186. The company has a fifty day moving average price of $280.24 and a 200 day moving average price of $309.15. The company has a market capitalization of $140.16 billion, a price-to-earnings ratio of 33.39, a PEG ratio of 2.91 and a beta of 0.56. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. During the same period in the previous year, the firm earned $4.96 earnings per share. Amgen’s revenue for the quarter was up 23.2% on a year-over-year basis. On average, analysts predict that Amgen Inc. will post 19.53 earnings per share for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a $2.38 dividend. The ex-dividend date is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.65%. Amgen’s dividend payout ratio (DPR) is 121.90%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.